Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $45.32 and last traded at $45.02, with a volume of 119780 shares traded. The stock had previously closed at $43.09.
Gemini Therapeutics Stock Performance
The stock has a market cap of $1.95 billion, a P/E ratio of -43.09 and a beta of -0.12. The company’s fifty day moving average price is $43.39 and its 200-day moving average price is $46.76.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- How to Invest in Silver: A Beginner’s Guide
- Most Volatile Stocks, What Investors Need to Know
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
